These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31061068)

  • 41. A comprehensive review of pacritinib in myelofibrosis.
    Verstovsek S; Komrokji RS
    Future Oncol; 2015; 11(20):2819-30. PubMed ID: 26367195
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.
    Mead AJ; Milojkovic D; Knapper S; Garg M; Chacko J; Farquharson M; Yin J; Ali S; Clark RE; Andrews C; Dawson MK; Harrison C
    Br J Haematol; 2015 Jul; 170(1):29-39. PubMed ID: 25824940
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis.
    Erba BG; Gruppi C; Corada M; Pisati F; Rosti V; Bartalucci N; Villeval JL; Vannucchi AM; Barosi G; Balduini A; Dejana E
    Am J Pathol; 2017 Aug; 187(8):1879-1892. PubMed ID: 28728747
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
    Deininger M; Radich J; Burn TC; Huber R; Paranagama D; Verstovsek S
    Blood; 2015 Sep; 126(13):1551-4. PubMed ID: 26228487
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Megakaryocytes in Myeloproliferative Neoplasms Have Unique Somatic Mutations.
    Guo BB; Allcock RJ; Mirzai B; Malherbe JA; Choudry FA; Frontini M; Chuah H; Liang J; Kavanagh SE; Howman R; Ouwehand WH; Fuller KA; Erber WN
    Am J Pathol; 2017 Jul; 187(7):1512-1522. PubMed ID: 28502479
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
    Yan D; Pomicter AD; Tantravahi S; Mason CC; Senina AV; Ahmann JM; Wang Q; Than H; Patel AB; Heaton WL; Eiring AM; Clair PM; Gantz KC; Redwine HM; Swierczek SI; Halverson BJ; Baloglu E; Shacham S; Khorashad JS; Kelley TW; Salama ME; Miles RR; Boucher KM; Prchal JT; O'Hare T; Deininger MW
    Clin Cancer Res; 2019 Apr; 25(7):2323-2335. PubMed ID: 30563936
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ruxolitinib.
    Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R
    Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.
    Ostojic A; Vrhovac R; Verstovsek S
    Future Oncol; 2011 Sep; 7(9):1035-43. PubMed ID: 21919691
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Primary myelofibrosis--pathogenesis, diagnosis and treatment].
    Ghanima W; Knutsen H; Delabie J; Bruserud Ø
    Tidsskr Nor Laegeforen; 2013 Oct; 133(18):1946-50. PubMed ID: 24084971
    [TBL] [Abstract][Full Text] [Related]  

  • 50. JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.
    Evrot E; Ebel N; Romanet V; Roelli C; Andraos R; Qian Z; Dölemeyer A; Dammassa E; Sterker D; Cozens R; Hofmann F; Murakami M; Baffert F; Radimerski T
    Clin Cancer Res; 2013 Nov; 19(22):6230-41. PubMed ID: 24081976
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pathophysiological mechanisms operating in the development of myelofibrosis: role of megakaryocytes.
    Castro-Malaspina H; Moore MA
    Nouv Rev Fr Hematol (1978); 1982; 24(4):221-6. PubMed ID: 6292827
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.
    Desterke C; Martinaud C; Guerton B; Pieri L; Bogani C; Clay D; Torossian F; Lataillade JJ; Hasselbach HC; Gisslinger H; Demory JL; Dupriez B; Boucheix C; Rubinstein E; Amsellem S; Vannucchi AM; Le Bousse-Kerdilès MC
    Haematologica; 2015 Jun; 100(6):757-67. PubMed ID: 25840601
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.
    Cervantes F; Vannucchi AM; Kiladjian JJ; Al-Ali HK; Sirulnik A; Stalbovskaya V; McQuitty M; Hunter DS; Levy RS; Passamonti F; Barbui T; Barosi G; Harrison CN; Knoops L; Gisslinger H;
    Blood; 2013 Dec; 122(25):4047-53. PubMed ID: 24174625
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN.
    Gleitz HFE; Dugourd AJF; Leimkühler NB; Snoeren IAM; Fuchs SNR; Menzel S; Ziegler S; Kröger N; Triviai I; Büsche G; Kreipe H; Banjanin B; Pritchard JE; Hoogenboezem R; Bindels EM; Schumacher N; Rose-John S; Elf S; Saez-Rodriguez J; Kramann R; Schneider RK
    Blood; 2020 Oct; 136(18):2051-2064. PubMed ID: 32726410
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis.
    Gilles L; Arslan AD; Marinaccio C; Wen QJ; Arya P; McNulty M; Yang Q; Zhao JC; Konstantinoff K; Lasho T; Pardanani A; Stein B; Plo I; Sundaravel S; Wickrema A; Migliaccio A; Gurbuxani S; Vainchenker W; Platanias LC; Tefferi A; Crispino JD
    J Clin Invest; 2017 Apr; 127(4):1316-1320. PubMed ID: 28240607
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ruxolitinib: a review of its use in patients with myelofibrosis.
    Plosker GL
    Drugs; 2015 Feb; 75(3):297-308. PubMed ID: 25601187
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
    Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of megakaryocyte proliferation of the evolution of myelofibrosis. Histological follow-up study in 186 patients with chronic myeloid leukaemia.
    Buhr T; Choritz H; Georgii A
    Virchows Arch A Pathol Anat Histopathol; 1992; 420(6):473-8. PubMed ID: 1609507
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
    Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
    PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
    Randhawa J; Ostojic A; Vrhovac R; Atallah E; Verstovsek S
    J Hematol Oncol; 2012 Aug; 5():43. PubMed ID: 22852872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.